CAR Immunotherapy for the Treatment of Infectious Diseases: a Systematic Review

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Feb 14

PMID 38352878

Authors

Elena Morte-Romea

Cecilia Pesini

Galadriel Pellejero-Sagastizabal

Santiago Letona-Gimenez

Luis Martinez-Lostao

Silvia Loscos Aranda

Carla Toyas

Sergio Redrado

Elena Dolader-Ballesteros

Maykel Arias

Eva M Galvez

Rebeca Sanz-Pamplona

Julian Pardo

Jose Ramon Pano-Pardo

Ariel Ramirez-Labrada

Affiliations

Soon will be listed here.

Abstract

Immunotherapy treatments aim to modulate the host's immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections.

Citing Articles

Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases.

Hernandez-Lopez A, Olaya-Vargas A, Bustamante-Ogando J, Meneses-Acosta A Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005970 PMC: 11858291. DOI: 10.3390/ph18020156.

Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches.

Abba Moussa D, Vazquez M, Chable-Bessia C, Roux-Portalez V, Tamagnini E, Pedotti M Emerg Microbes Infect. 2024; 14(1):2432345.

PMID: 39584380 PMC: 11632933. DOI: 10.1080/22221751.2024.2432345.

Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies.

Zhang W, Zeng M, Li Y, Yu L Biomark Res. 2024; 12(1):71.

PMID: 39075601 PMC: 11287861. DOI: 10.1186/s40364-024-00617-6.

Engineering strategies to safely drive CAR T-cells into the future.

Rossi M, Breman E Front Immunol. 2024; 15:1411393.

PMID: 38962002 PMC: 11219585. DOI: 10.3389/fimmu.2024.1411393.

References

Seif M, Einsele H, Loffler J . CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases. Front Immunol. 2019; 10:2711. PMC: 6881243. DOI: 10.3389/fimmu.2019.02711. View

Isaacson M, Compton T . Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol. 2009; 83(8):3891-903. PMC: 2663263. DOI: 10.1128/JVI.01251-08. View

Coley W . The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991; (262):3-11. View

Trapani J, Smyth M . Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002; 2(10):735-47. DOI: 10.1038/nri911. View

Savoldo B, Rooney C, Di Stasi A, Abken H, Hombach A, Foster A . Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007; 110(7):2620-30. PMC: 1988944. DOI: 10.1182/blood-2006-11-059139. View

Fu W, Lei C, Ma Z, Qian K, Li T, Zhao J . CAR Macrophages for SARS-CoV-2 Immunotherapy. Front Immunol. 2021; 12:669103. PMC: 8343226. DOI: 10.3389/fimmu.2021.669103. View

Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518. PMC: 4058440. DOI: 10.1056/NEJMoa1215134. View

Yang O, Tran A, Kalams S, Johnson R, Roberts M, Walker B . Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A. 1997; 94(21):11478-83. PMC: 23511. DOI: 10.1073/pnas.94.21.11478. View

Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard J . Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med. 1996; 2(3):338-42. DOI: 10.1038/nm0396-338. View

10.

Klopp A, Schreiber S, Kosinska A, Pule M, Protzer U, Wisskirchen K . Depletion of T cells Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B. Front Immunol. 2021; 12:734246. PMC: 8527178. DOI: 10.3389/fimmu.2021.734246. View

11.

Cerwenka A, Lanier L . Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016; 16(2):112-23. DOI: 10.1038/nri.2015.9. View

12.

Naran K, Nundalall T, Chetty S, Barth S . Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Front Microbiol. 2019; 9:3158. PMC: 6308495. DOI: 10.3389/fmicb.2018.03158. View

13.

Karschnia P, Jordan J, Forst D, Arrillaga-Romany I, Batchelor T, Baehring J . Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019; 133(20):2212-2221. DOI: 10.1182/blood-2018-12-893396. View

14.

Romeo C, Seed B . Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991; 64(5):1037-46. DOI: 10.1016/0092-8674(91)90327-u. View

15.

Keller M, Harris K, Jensen-Wachspress M, Kankate V, Lang H, Lazarski C . SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood. 2020; 136(25):2905-2917. PMC: 7746091. DOI: 10.1182/blood.2020008488. View

16.

Full F, Lehner M, Thonn V, Goetz G, Scholz B, Kaufmann K . T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol. 2010; 84(8):4083-8. PMC: 2849495. DOI: 10.1128/JVI.02117-09. View

17.

Garcia-Mulero S, Fornelino R, Punta M, Lise S, Varela M, Del Carpio L . Driver mutations in and genes as potential targets for precision immunotherapy in uveal melanoma patients. Oncoimmunology. 2023; 12(1):2261278. PMC: 10732647. DOI: 10.1080/2162402X.2023.2261278. View

18.

Berzins S, Smyth M, Baxter A . Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011; 11(2):131-42. DOI: 10.1038/nri2904. View

19.

Choi G, Shin G, Bae S . Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. Int J Environ Res Public Health. 2022; 19(19). PMC: 9566791. DOI: 10.3390/ijerph191912366. View

20.

Ahsan N, Kanda T, Nagashima K, Takada K . Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production. J Virol. 2005; 79(7):4415-24. PMC: 1061545. DOI: 10.1128/JVI.79.7.4415-4424.2005. View